Ali-Jackson Kamil
SEC Form 4 insider trading activity
Ali-Jackson Kamil has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jun 24, 2026.
On the most recent filing, Ali-Jackson Kamil is listed as Director at RIGEL PHARMACEUTICALS INC. Inside the rolling window, Ali-Jackson Kamil reported no open-market purchases and 2 open-market sales totaling $160K in RIGL. The largest disclosed transaction in the window is a sale of 2,500 RIGL shares on Jun 22, 2026, worth $88K.
Companies traded
Other insiders at RIGL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$160K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Ali-Jackson Kamil made?
Ali-Jackson Kamil has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Ali-Jackson Kamil trade?
Ali-Jackson Kamil has filed SEC Form 4 disclosures for 1 company, including RIGL.
When was Ali-Jackson Kamil's most recent SEC Form 4 filing?
Ali-Jackson Kamil's most recent SEC Form 4 filing on Tracefour is dated Jun 24, 2026.
What is Ali-Jackson Kamil's total buy and sell value in the current window?
Inside the rolling retention window, Ali-Jackson Kamil bought $0 and sold $160K based on SEC Form 4 filings.
What was Ali-Jackson Kamil's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,500 RIGL shares on 2026-06-22, worth $88K, per SEC Form 4 filings.